Patients Social media advocacy: Healthcare professionals and the Trea... Social media is a hub of opinion, argument, and advocacy that traverses a virtually endless spectrum.
News Novo Nordisk leaps on new obesity drug data Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.
News Large study points to benefits - and risks - of GLP-1 drugs The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.
News High-dose semaglutide ramps up weight loss, says Novo Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.
News Lilly trims sales forecast on weaker obesity/diabetes growth Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.
News Obesity needs a new definition, says global commission Experts think the current way of defining obesity based on BMI isn't nuanced enough to gauge health and the need for weight-loss therapies.
News UK, pharma industry pilot rapid access routes for medicines A series of pilot schemes set up by the UK in partnership with the pharma industry will test ways to get new medicines to patients more quickly.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
